Conclusions of the Ib safety trial were presented in ESMO 2021

ESMO

The conclusions of the Ib safety trial required by the EMA (to demonstrate safety prior to the start of Phase IIb/III) were presented in ESMO 2021 Congress in Paris selected as an Oral Presentation, showed that the dosage used for our trial was 12g/day of 2OHOA is well tolerated and safe in combination with the SoC. The results were presented by Dr. Balañà, a member of the Ethics Board of the CLINGLIO project and IP from the Ib phase trial.
For more information on the results:
Balañà et al. 346MO - Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial. Annals of Oncology (2021) 32 (suppl_5): S516-S529. 10.1016/annonc/annonc674